1-3 of 3
Missak Haigentz
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)

Missak Haigentz, Jr, Jeannette Y. Lee, Elizabeth Y. Chiao, David M. Aboulafia, Lee Ratner, Richard F. Ambinder, Robert A. Baiocchi, Ronald T. Mitsuyasu, William Wachsman, Joseph A. Sparano, Michelle A. Rudek
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (24): 5038–5046.
https://doi.org/10.1158/1078-0432.CCR-23-1142
Published: 15 December 2023
View article titled, Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)
Open the PDF for Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087) in another window
Includes: Supplementary data
Journal Articles

Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus–Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Charu Aggarwal, Nabil F. Saba, Alain Algazi, Ammar Sukari, Tanguy Y. Seiwert, Missak Haigentz, Mercedes Porosnicu, Marcelo Bonomi, Jean Boyer, Mark T. Esser, Lily I. Cheng, Sonia Agrawal, Emily C. Jennings, Nicholas M. Durham, Karl Fraser, Delphine Lissa, Maozhen Gong, Natalia Ceaicovscaia, Amaya Gascó Hernández, Rakesh Kumar
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (3): 560–570.
https://doi.org/10.1158/1078-0432.CCR-22-1987
Published: 01 February 2023
View article titled, Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus–Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Open the PDF for Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus–Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

A Phase 1 Open-Label, Accelerated Dose-Escalation Study of the Hypoxia-Activated Prodrug AQ4N in Patients with Advanced Malignancies

Kyriakos P. Papadopoulos, Sanjay Goel, Murali Beeram, Alvin Wong, Kavita Desai, Missak Haigentz, María L. Milián, Sridhar Mani, Anthony Tolcher, Alshad S. Lalani, John Sarantopoulos
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (21): 7110–7115.
https://doi.org/10.1158/1078-0432.CCR-08-0483
Published: 03 November 2008
View article titled, A Phase 1 Open-Label, Accelerated Dose-Escalation Study of the Hypoxia-Activated Prodrug AQ4N in Patients with Advanced Malignancies
Open the PDF for A Phase 1 Open-Label, Accelerated Dose-Escalation Study of the Hypoxia-Activated Prodrug AQ4N in Patients with Advanced Malignancies in another window